Sage Mountain Advisors LLC Increases Stock Position in Edwards Lifesciences Corporation $EW

Sage Mountain Advisors LLC boosted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 26.5% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,689 shares of the medical research company’s stock after purchasing an additional 773 shares during the quarter. Sage Mountain Advisors LLC’s holdings in Edwards Lifesciences were worth $289,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in EW. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences during the first quarter worth approximately $26,000. SouthState Corp purchased a new position in shares of Edwards Lifesciences during the first quarter worth approximately $27,000. Rosenberg Matthew Hamilton purchased a new position in shares of Edwards Lifesciences during the second quarter worth approximately $28,000. Tradewinds Capital Management LLC raised its stake in shares of Edwards Lifesciences by 102.5% during the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock worth $29,000 after acquiring an additional 205 shares in the last quarter. Finally, Rossby Financial LCC purchased a new position in shares of Edwards Lifesciences during the first quarter worth approximately $29,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EW has been the topic of several research reports. Wall Street Zen downgraded shares of Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Oppenheimer downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Wells Fargo & Company lifted their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $87.06.

Insiders Place Their Bets

In related news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider owned 206,900 shares in the company, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.34% of the stock is currently owned by company insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $76.15 on Monday. The stock has a market cap of $44.70 billion, a P/E ratio of 10.96, a price-to-earnings-growth ratio of 3.65 and a beta of 1.05. The firm’s fifty day simple moving average is $77.37 and its 200 day simple moving average is $76.48. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.70 earnings per share. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.